UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

Breast cancer research and treatment, 2015-05, Vol.151 (1), p.57-73

2015

Volltextzugriff (PDF)

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

Clinical cancer research, 2019-02, Vol.25 (3), p.921-927

2019

Volltextzugriff (PDF)

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

EMBO molecular medicine, 2019-02, Vol.11 (2), p.n/a

2019

Volltextzugriff (PDF)

Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition

Journal of investigative dermatology, 2020-11, Vol.140 (11), p.2242-2252.e7

2020

Volltextzugriff (PDF)

Playing the melanoma endgame

Clinical cancer research, 2018-10, Vol.24 (19), p.4629-4630

2018

Volltextzugriff (PDF)

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms

Cancer discovery, 2018-05, Vol.8 (5), p.568-581

2018

Volltextzugriff (PDF)

Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma

Molecular cancer therapeutics, 2020-08, Vol.19 (8), p.1719-1726

2020

Volltextzugriff (PDF)

Glutamatergic signaling in cellular transformation

Pigment cell and melanoma research, 2012-05, Vol.25 (3), p.331-342

2012

Volltextzugriff (PDF)

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma

Cancer research (Chicago, Ill.), 2016-09, Vol.76 (18), p.5455-5466

2016

Volltextzugriff (PDF)

Frizzled with age: an opportunity for 'gerontological medicine'

Pigment cell and melanoma research, 2016-09, Vol.29 (5), p.488-489

Teh, Jessica L. F.

2016

Volltextzugriff (PDF)

Activation of CD8 + T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors

Cancer immunology research, 2020-09, Vol.8 (9), p.1114-1121

2020

Volltextzugriff (PDF)

Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor

Pigment cell and melanoma research, 2014-07, Vol.27 (4), p.621-629

2014

Volltextzugriff (PDF)

Abstract 3096: CDK4/6 as a therapeutic target in malignant melanoma

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3096-3096

2015

Volltextzugriff (PDF)

Abstract 2986: NR2F1 underlies persistence of residual disease in melanoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2986-2986

2020

Volltextzugriff (PDF)

Abstract 5199: An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.5199-5199

2016

Volltextzugriff (PDF)

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms

Cancer discovery, 2018-12, Vol.8 (12), p.1654-1654

2018

Volltextzugriff (PDF)

A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

Cancer discovery, 2018-05, Vol.8 (5), p.556-567

2018

Volltextzugriff (PDF)

Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma

Cancer research (Chicago, Ill.), 2023-01, Vol.83 (2_Supplement_1), p.A005-A005

2023

Volltextzugriff (PDF)

A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling

Cancer discovery, 2018-03, Vol.8 (5), p.556-567

2018

Volltextzugriff (PDF)

Towards a sustainable and equitable blue economy

Nature sustainability, 2019-11, Vol.2 (11), p.991-993

2019

Volltextzugriff (PDF)

Tu1172 QUANTIFYING ARTIFICIAL SWEETENERS AND EMULSIFIERS IN CROHN'S DISEASE AND THEIR RELATIONSHIP WITH DISEASE WITH DISEASE ACTIVITY. THE ENIGMA STUDY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1269-S-1269

2024

Volltextzugriff (PDF)

The TNF Receptor Superfamily-NF-κB Axis Is Critical to Maintain Effector Regulatory T Cells in Lymphoid and Non-lymphoid Tissues

Cell reports (Cambridge), 2017-09, Vol.20 (12), p.2906-2920

2017

Volltextzugriff (PDF)

Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia

Circulation (New York, N.Y.), 2015-02, Vol.131 (8), p.730-741

2015

Volltextzugriff (PDF)

Tranexamic Acid in Patients Undergoing Noncardiac Surgery

The New England journal of medicine, 2022-05, Vol.386 (21), p.1986-1997

2022

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(66)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition

Playing the melanoma endgame

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms

Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma

Glutamatergic signaling in cellular transformation

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma

Frizzled with age: an opportunity for 'gerontological medicine'

Activation of CD8 + T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors

Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor

Abstract 3096: CDK4/6 as a therapeutic target in malignant melanoma

Abstract 2986: NR2F1 underlies persistence of residual disease in melanoma

Abstract 5199: An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms

A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma

A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling

Towards a sustainable and equitable blue economy

Tu1172 QUANTIFYING ARTIFICIAL SWEETENERS AND EMULSIFIERS IN CROHN'S DISEASE AND THEIR RELATIONSHIP WITH DISEASE WITH DISEASE ACTIVITY. THE ENIGMA STUDY

The TNF Receptor Superfamily-NF-κB Axis Is Critical to Maintain Effector Regulatory T Cells in Lymphoid and Non-lymphoid Tissues

Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia

Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Suchergebnisse filtern